Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 2:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 75 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Terminated Phase 4 Interventional Results available

Protocolized Diuretic Strategy in Cardiorenal Failure

NCT01921829
Conditions
Cardiac Failure, Renal Failure, Kidney Failure
Interventions
Protocolized Diuretic Strategy
Drug
Lead sponsor
Kelly V. Liang, MD
Other
Eligibility
21 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Shiga Toxin-Producing Escherichia Coli (E. Coli) Infection, Hemolytic-Uremic Syndrome
Interventions
Infusion of 200% maintenance fluids as balanced crystalloid IV solution, Oral fluids; infusion of up to 110% maintenance fluids as balanced crystalloid IV solution
Other
Lead sponsor
University of Calgary
Other
Eligibility
9 Months to 21 Years
Enrollment
1,040 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
22
States / cities
Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 19 more
Conditions
Acute Kidney Injury, Fluid Overload, Ultrasonography
Interventions
Portal vein flow, Intra-renal flow, Hepatic vein flow, Pulmonary B-lines, Dimensions of the inferior vena cava, Left ventricular function, Right ventricular function
Diagnostic Test
Lead sponsor
Centre hospitalier de l'Université de Montréal (CHUM)
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Lexington, Kentucky
Conditions
Heart Failure, Congestive Heart Failure, Cardiomyopathy
Interventions
Not listed
Lead sponsor
Medtronic Cardiac Rhythm and Heart Failure
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
16
States / cities
Several Locations, California • Gainsville, Florida • Atlanta, Georgia + 13 more
Conditions
Euvolemic Hyponatremia, Hypervolemic Hyponatremia
Interventions
Not listed
Lead sponsor
Otsuka America Pharmaceutical
Industry
Eligibility
18 Years and older
Enrollment
5,028 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
72
States / cities
Azusa, California • Inglewood, California • Los Angeles, California + 58 more
Conditions
Respiratory Failure, Volume Overload, Hypernatremia
Interventions
Supplemental metolazone diuresis, Placebo Comparator: Control-- furosemide (lasix) only
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Hyponatremia With Normal Extracellular Fluid Volume
Interventions
lixivaptan, placebo
Drug
Lead sponsor
CardioKine Inc.
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
38
States / cities
Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 32 more
Completed Not applicable Interventional

DORAYA-HF Early Feasibility Study

NCT05206422
Conditions
Acute Decompensated Heart Failure
Interventions
Doraya Catheter
Device
Lead sponsor
Revamp Medical Inc.
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
14
States / cities
San Francisco, California • Weston, Florida • Augusta, Georgia + 9 more
Conditions
Chronic Kidney Disease, Hypertension
Interventions
Diuretic augmentation (hydrochlorothiazide, chlorthalidone, furosemide, torsemide, or bumetanide)
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Houston, Texas
Not listed No phase listed Observational Accepts healthy volunteers

The Effect of Fluids on Aortic VTI During C-section

NCT04330742
Conditions
Pregnancy Related, Hemorrhage, Fluid Overload, Labor Complication
Interventions
lactated ringers
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Houston, Texas
Conditions
Hyponatremia
Interventions
lixivaptan, Placebo
Drug
Lead sponsor
CardioKine Inc.
Industry
Eligibility
18 Years and older
Enrollment
652 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
102
States / cities
Birmingham, Alabama • Mobile, Alabama • Bakersfield, California + 82 more
Conditions
Healthy Participants
Interventions
BMS-986308, Placebo (for BMS-986308), Furosemide
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Lenexa, Kansas
Conditions
Fluid Overload, Glomerulosclerosis, Focal Segmental, Edema, Membranous Nephropathy, Minimal Change Disease, Minimal Change Nephrotic Syndrome, IgM Nephropathy, Nephrotic Syndrome, Glomerular Disease, Nephrotic Syndrome, Minimal Change, Nephrotic Syndrome in Children, Nephrotic Syndrome With Edema (Diagnosis), FSGS
Interventions
Interview
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
2 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Fluid Overload and Hypertension in Hemodialysis Patients
Interventions
5% dextrose solution
Other
Lead sponsor
Renal Research Institute
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
New York, New York
Completed No phase listed Observational Accepts healthy volunteers

Changes in Pituitary Iron and Volume With Deferasirox

NCT01376622
Conditions
Iron Overload
Interventions
Not listed
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
2 Years to 25 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Vascular Hypotension, Hypovolemia, Hypervolemia
Interventions
Control Group, Treatment Group
Other
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Loma Linda, California
Conditions
Edema, Hypervolemia, Chronic Kidney Diseases, Nephrotic Syndrome
Interventions
Diuretic Tuner
Device
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Hemodialysis Complication, Fluid Overload, Dialysis Disequilibrium, Intra-dialytic Hypotension, Hypertension
Interventions
Dialysate Sodium Lowering
Other
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Respiratory Insufficiency
Interventions
Not listed
Lead sponsor
Smiths Medical, ASD, Inc.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Chronic Kidney Disease
Interventions
Diuretic initiation or augmentation
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Acute Kidney Injury, Fluid Overload, Prematurity Complications, Risk Factors, Epidemiology, Chronic Kidney Disease(CKD), Hypertension
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
0 Minutes to 2 Weeks
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
50
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Palo Alto, California + 45 more
Conditions
Infection, Hypervolemia, Hypovolemia, Septic Shock, Acute Heart Failure, Congestive Heart Failure
Interventions
Peripheral Intravenous Analysis (PIVA), Non-invasive fluid response measure, Passive leg raise (PLR)
Procedure · Diagnostic Test
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
3
States / cities
Boston, Massachusetts • Worcester, Massachusetts • Seattle, Washington
Conditions
Congestive Heart Failure
Interventions
Lixivaptan, Placebo
Drug
Lead sponsor
CardioKine Inc.
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
25
States / cities
Mobile, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 22 more
Conditions
Heart Failure
Interventions
sc2Wear Furosemide Infusor
Combination Product
Lead sponsor
Steward St. Elizabeth's Medical Center of Boston, Inc.
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Brighton, Massachusetts